Anabasum

Preclinical Phase 1 Phase 2 Phase 3
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Anabasum (JBT-101 or Resunab) is a first in class, synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Anabasum has the potential to be a safe and potent anti-inflammatory drug with a unique mechanism of action to treat a range of chronic inflammatory diseases. Anabasum is currently being evaluated for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ("systemic sclerosis"), dermatomyositis and systemic lupus erythematosus, four indications in which inflammation contributes to disease progression. In November 2016, Corbus reported positive topline data results from a Phase 2 study in systemic sclerosis, showing clear signal of clinical benefit with anabasum. The Company recently completed a Phase 2 study of anabasum for the treatment of cystic fibrosis with topline data expected to be announced by the end of the first quarter of 2017. Additionally, Anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis, with a 12-month open-label extension study in dermatomyositis and another Phase 2 study in systemic lupus erythematosus planned to commence in the second quarter of 2017.

Pre-clinical and Phase 1 clinical studies (123 subjects) have shown anabasum to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in pre-clinical models of inflammation and fibrosis. Anabasum triggers the production of "Specialized Pro-resolving Lipid Mediators" (SPMs) that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Anabasum has direct effects on fibroblasts to halt tissue scarring. In effect, anabasum triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

Anabasum has demonstrated promising efficacy data in several pre-clinical models including ones specific to cystic fibrosis and systemic sclerosis. Patient ex vivo data showed similar promise including in cells derived from systemic sclerosis, dermatomyositis and SLE patients.

Anabasum is currently being evaluated in four separate Phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis, and dermatomyositis and systemic lupus erythematosus. To learn more about Corbus' ongoing clinical trials, please click on one of the below links or visit clinicaltrials.gov.


Anabasum Videos